Raymond James Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $70.00
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […]
More Stories
Smartsheet (NYSE:SMAR) Earns Neutral Rating from Citigroup
Citigroup reissued their neutral rating on shares of Smartsheet (NYSE:SMAR – Free Report) in a research note issued to investors...
Camping World (NYSE:CWH) PT Raised to $30.00
Camping World (NYSE:CWH – Free Report) had its price objective increased by Monness Crespi & Hardt from $24.00 to $30.00...
Oppenheimer Boosts DoorDash (NASDAQ:DASH) Price Target to $160.00
DoorDash (NASDAQ:DASH – Free Report) had its price target boosted by Oppenheimer from $145.00 to $160.00 in a research note...
Reviewing ASICS (OTCMKTS:ASCCF) and adidas (OTCMKTS:ADDYY)
ASICS (OTCMKTS:ASCCF – Get Free Report) and adidas (OTCMKTS:ADDYY – Get Free Report) are both consumer cyclical companies, but which...
Comparing Lithia Motors (NYSE:LAD) and AutoCanada (OTCMKTS:AOCIF)
AutoCanada (OTCMKTS:AOCIF – Get Free Report) and Lithia Motors (NYSE:LAD – Get Free Report) are both consumer cyclical companies, but...
INmune Bio (NASDAQ:INMB) Earns Outperform Rating from Analysts at Raymond James
Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB – Free Report) in a research report released on Friday...